Conference presentation

RNS Number : 6506R
Physiomics PLC
12 November 2021
 

12 November 2021

 

Physiomics plc

("Physiomics") or ("the Company")

 

Conference presentation

 

Physiomics and Bicycle Therapeutics to present on preclinical modelling of an immune therapy at SITC 2021 Annual Meeting

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is presenting a poster at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting taking place at the Walter E. Washington Convention Center, Washington, USA from 10-14 November 2021.

 

The Company and its client Bicycle Therapeutics will today be presenting an original poster (abstract #826) in an ePoster format.  The poster is titled "Establishing the preclinical/translational PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)".

 

The Company's modelling determined that the level of tumour infiltrating CD8+ T-cells fully captures the treatment effect of BT7480 on tumour growth in an in vivo preclinical model. A PK/PD modelling framework was developed that predicts preclinical biomarker level and tumour growth inhibition in response to changes in the BT7480 dose and dosing schedule.

 

More information about the conference can be found using the following link: https://www.sitcancer.org/2021/home

 

The poster is now available on the Physiomics website at this link: https://www.physiomics.co.uk/resources/ .  

 

Enquiries:

 

Physiomics plc 

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAZZMGMGRDGMZM

Companies

Physiomics (PYC)
UK 100

Latest directors dealings